Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;22:318. doi: 10.1186/s12935-022-02634-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 9 — STEAP3 supplemented with PD-L2 predict sorafenib efficacy in HCC patients. A The differential of the gene expression of STEAP3 in sorafinib response and non-response patients. B, C The distribution of number of responders and non-responders with low/high expression of STEAP3, which is below/above the threshold. D The statistic results showing that the accuracy of the biomarker (STEAP3) in non-responsive HCC patients with sorafinib therapy. E The differential of the gene expression of PD-L2 in sorafinib response and non-response patients. F, G The distribution of number of responders and non-responders with low/high expression of PD-L2 (below/above the threshold), as STEAP3 is low expression. L The statistic results showing that the accuracy of these biomarkers (STEAP3 and PD-L2) in responsive and non-responsive HCC patients with sorafinib therapy